Dana-farber-cancer Institute Inc.

Washington University

Andrew L Kung

David M Livingston

Pallab Banerjee

Constantine S Mitsiades

Nicholas Mitsiades

David Ziegler

Joshua Rubin

Nicholos Mitsiades

Shoumo Bhattacharya

The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.

NOL3 is a predictor of patient outcome

The invention provides compounds and methods of their use in the detection of apoptosis and necrosis both in vitro and in vivo. Also provided are compounds and methods of their use in selective delivery of agents to cells undergoing apoptosis or necrosis. The compounds and methods are based on conjugates formed with a dehydrogenase such as lactate dehydrogenase, alcohol dehydrogenase, aldehyde dehydrogenase, and malate dehydrogenase. The compounds and methods are useful in the diagnosis and treatment of conditions characterized by apoptosis, including cancer, cardiac disease, neurologic disease including stroke, and autoimmunity. The compounds and methods offer distinct advantages over corresponding compounds and methods based on Annexin V. Also provided are methods for screening for compounds that modulate, i.e., inhibit or promote, apoptosis.

Compositions for detecting cell death and methods of use thereof

The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phosphospecific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods.

Phosphospecific chemokine receptor antibodies

The invention methods using a insulin-like growth factor receptor inhibitor to inhibit tumor cell growth in a subject in need thereof.

Methods for inhibiting tumor cell growth

The invention relates to compositions containing a polynucleotide encoding for a reporter gene, a selectable marker and a regulatory element, that provide a method for imaging cells in vivo.

Composition and method for imaging cells

The invention provides methods for identifying compounds that can be used to modify transcriptional responses to hypoxia, and use of such compounds in therapeutic and diagnostic methods.

Growing community of inventors

Roslindale, MA, United States of America

Andrew L Kung